Distinct altered patterns of p27(KIP1) gene expression in benign prostatic hyperplasia and prostatic carcinoma

Journal of the National Cancer Institute

Volumn 90, Issue 17, 1998, Pages 1284-1291

  Cordon Cardo, Carlos ^a   Koff, Andrew ^a   Drobnjak, Marija ^a   Capodieci, Paola ^a   Osman, Iman ^a   Millard, S Sean ^a   Gaudin, Paul B ^a   Fazzari, Melissa ^a   Zhang, Zuo Feng ^a   Massague, Joan ^b   Scher, Howard I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; EPITHELIUM CELL; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; REGRESSION ANALYSIS;

EID: 0032475438     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.17.1284     Document Type: Article

References (56)

1. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266:1821-8.
2. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-60.
3. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
4. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
5. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
6. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1. a potential mediator of p53 tumor suppression. Cell 1993;75: 817-25.
7. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
8. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, et al. p27Kip1, a cyclin-Cdk inhibitor. links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9-22.
9. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78: 59-66.
10. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
11. Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-49.
12. Matsuoka M, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995;9: 650-62.
13. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366: 704-7.
14. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994;371:257-61.
15. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X. O'Keefe CL, et al. Growth suppression by p18, a p16INK4/MTS1-and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994;8:2939-52.
16. Chan FK, Zhang J, Cheng L, Shapiro DN, Winoto A. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol Cell Biol 1995;15:2682-8.
17. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994;8: 9-22.
18. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 1994;79:487-96.
19. Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996;272: 877-80.
20. Luo Y, Marx SO, Kiyokawa H, Koff A, Massague J, Marks AR. Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol 1996; 16:6744-51.
21. Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H, Koff A. Enhanced ribosomal association of p27 (Kip1) mRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem 1997;272: 7093-8.
22. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, et al. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995;55: 1211-4.
23. Pietenpol JA, Bohlander SK, Sato Y, Rowley JD, Papadopoulos N, Liu B, et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995;55:1206-10.
24. Bullrich F, MacLachlan TK, Sang N, Druck T, Veronese ML, Allen SL, et al. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor. p27Kip1, to regions involved in human cancer. Cancer Res 1995;55: 1199-205.
25. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3: 231-4.
26. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E. alone and in combination. correlate with survival in young breast cancer patients Nat Med 1997;3:222-5
27. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997:3: 227-30.
28. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (Tla.b) invasive breast carcinomas. Cancer 1997;57:1259-63.
29. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
30. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-38.
31. SAS Institute, Inc. SAS/STAT user guide. version 6. Cary (NC): SAS Institute. Inc.: 1990
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958;53:457-81.
33. Daniel WW. Applied non-parametric statistics. Philadelphia: PWS-KENT Publishing Co.: 1990. p. 90.
34. Daniel WW. Applied non-parametric statistics. Philadelphia: PWS-KENT Publishing Co.: 1990. p. 220.
35. Maritz JS. Distribution-free statistical methods. New York: Chapman and Hall; 1981.
36. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269: 682-5.
37. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996;274:1652-9.
38. Hengst L, Sherr SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996;271:1861-4.
39. Chen Y, Robles AI, Martinez LA, Liu F, Gimenez-Conti IB, Conti CJ. Expression of G1 cyclins. cyclin-dependent kinases. and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ 1996;7:1571-8.
40. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996;85:721-32.
41. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85: 707-20.
42. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85: 733-44.
43. Gerlach C, Golding M, Larue L, Alison MR, Gerdes J. Ki-67 immunoexpression is a robust marker of proliferative cells in the rat. Lab Invest 1997;77:697-8.
44. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995;46:142-8.
45. Oesterling JE. Benign prostatic hyperplasia: a review of its histogonesis and natural history. Prostate Suppl 1996;6:67-73.
46. Linehan W, Cordon-Cardo C, Isaacs W. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Molecular biology of genitourinary cancers. Cancer: principles and practice of oncology. Philadelphia: Lippincott: 1997. p. 1253-71.
47. Bostwick DG. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 1996; 78:330-6.
48. Parkinson MC. Pre-neoplastic lesions of the prostate. Histopathology 1995; 27:301-11.
49. Bostwick DG, Pacelli A, Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate 1996;27:117-34.
50. Lipski BA, Garcia RL, Brawer MK. Prostatic intraepithelial neoplasia: significance and management. Semin Urol Oncol 1996;14:149-55.
51. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85: 1657-69.
52. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994;151:1276-80.
53. Brooks JD, Bova GS, Marshall FF, Isaacs WB. Tumor suppressor gene allelic loss in human renal cancers. J Urol 1993;150:1278-83.
54. Dinjens WN, van der Weiden MM, Schroeder FH, Bosman FT, Trapman J. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 1994;56:630-3.
55. Salem CE, Tomasic NA, Elmajian DA, Esrig D, Nichols PW, Taylor CR, et al. p53 protein and gene alterations in pathological stage C prostate carcinoma. J Urol 1997;158:510-4.
56. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997;89: 158-65.